Dr. McAneny is currently President of the American Medical Association (AMA). She has been a member of the AMA Board of Trustees since 2010, serving as its chair in 2015–2016. She has been a member of the American Society of Clinical Oncology (ASCO) Board of Directors, President of the New Mexico Medical Society (NMMS), and Founder and Chair for the board of the National Cancer Care Alliance.
Dr. McAneny is board certified in internal medicine, oncology, and hematology. Her interest is using data to improve practice sustainability began when she was appointed to the Centers for Medicare & Medicaid Service’s Practicing Physicians Advisory Council. In 2012, she received a $19.8 million grant from the Centers for Medicare & Medicaid Innovation to demonstrate how oncology practices can utilize triage pathways to lower costs while improving outcomes.
Dr. Von Hoff is currently Physician in Chief, Distinguished Professor of the Translational Research Division at TGen (Translational Genomics Research Institute) in Phoenix, Arizona. He is also Chief Scientific Officer for HonorHealth Clinical Research Institute, Medical Director of Research at McKesson Specialty Healthcare, and Scientific Medical Officer for US Oncology Research and leader of the Translation Oncology Program (TOP) specializing in phase I clinical trials done in the US Oncology Research network. He also is Professor of Medicine at Mayo Clinic in Scottsdale.
Dr. Von Hoff’s major interest is the development of new anticancer agents, both in the clinic and the laboratory.
Dr. Bunn is Distinguished Professor of Medicine and the James Dudley endowed Professor of Lung Cancer research at the University of Colorado Cancer Center and School of Medicine. He is also Director of the University of Colorado Comprehensive Cancer Center. He has been President of American Society of Clinical Oncology (ASCO), the International Association for the Study of Lung Cancer (IASLC), and the American Association of Cancer Institutes (AACI). He has served as Chairman of the FDA Oncology Drug Advisory Committee and Executive Director of the IASLC.
His major interest is novel therapies for the early detection and prevention of lung cancer. His studies have set standards for the treatment of lung cancer; they have identified issues of natural history and biomarkers to aid in prognosis and therapy selection.
Dr. Hahn is Associate Professor of Medicine at the Department of Oncology and the Department of Urology at Johns Hopkins University School of Medicine. He also is Director of the Medical Oncology Bladder Cancer Program. He also serves as the Bladder Cancer Committee Chair of the Eastern Cooperative Oncology Group (ECOG), participates in the National Cancer Institute’s Bladder Cancer Task Force, and serves on the scientific advisory board of the Bladder Cancer Advocacy Network.
Dr. Hahn is an internationally recognized authority in the conduct of bladder cancer novel therapeutic clinical trials and translational investigations.
Dr. Hamilton is a gastrointestinal and molecular pathologist, and Professor and Head of Pathology and Laboratory Medicine at The University of Texas MD Anderson Cancer Center (UTMDACC). He is an active member of the Eastern Cooperative Oncology Group and has published studies about the molecular pathology of colorectal cancer. He also has served as the Principal Investigator of the Cancer Center Support Grant-sponsored Tissue Biorepository and Pathology Resource core facility since 1998.
Dr. Hamilton’s area of interest includes developing biomarkers that help with the prognosis and prediction of the response to therapy that can improve patient survival and quality of life.